Buyback Announcements and News

10/27/2025

First Horizon National announces $1.2B share repurchase program ($20.99, 0.00)

  • First Horizon Corporation announced that its board has authorized a new $1.2B common stock repurchase program to replace the company's prior repurchase program, effective as of the close of business on 27-Oct-25.
    • The terminated program had ~$180M of remaining authorization and was set to expire on 31-Jan-26.
  • This new authorization will expire on 31-Jan-27.

10/27/2025

Insider transaction: Mueller Industries Chairman & CEO Gregory Christopher discloses sale of 350K shares - Form 4 ($103.71, 0.00)

  • Following the transaction, Christopher beneficially owns 1.2M shares, 1.1M directly/156K indirectly.

10/27/2025

Pebblebrook Hotel Trust board authorizes new share repurchase program of up to $150M - 8-K ($11.10, 0.00)

  • On 21-Oct-25, the board authorized a new share repurchase program of up to $150.0M of the company's outstanding common shares and concurrently terminated the company's prior common share repurchase program.
  • The program does not have an expiration date and may be suspended, modified or discontinued at any time.

10/27/2025

Insider transaction: Viridian Therapeutics holder Fairmount discloses purchase of 454.5K shares - Form 4 ($22.54, 0.00)

  • Fairmount beneficially owns 3.9M shares of common stock following the transaction.

10/27/2025

MVB Financial announces up to $10M stock repurchase program ($26.23, 0.00)

  • MVB Financial announced the authorization by the company's board of a stock repurchase program of up to $10M of MVB's company's common stock.
  • MVB intends to begin repurchasing stock in November 2025, and the stock repurchase program will expire upon the expenditure of $10M, when terminated or otherwise completed.

10/27/2025

Simpson Manufacturing Co. reports Q3 EPS $2.58 vs FactSet $2.41 [3 est, $2.37-2.45]; increases share repurchase authorization ($175.85, 0.00)

  • Reports Q3:
    • Revenue $623.5M vs FactSet $604.9M [3 est, $598-610.5M]
    • Adjusted EBITDA $155.3M vs FactSet $157.4M [3 est, $156.1-159.5M]
  • FY Guidance (Dec 2025):
    • Consolidated operating margin is estimated to be in the range of 19.0% to 20.0%, reflecting current market conditions and recent strategic initiatives. The outlook reflects the previously announced price increases that went into effect on 2-Jun-25 and 15-Oct-25 and it includes a benefit of $12.9M from the sale of the existing Gallatin, Tennessee facility as well as non-recurring severance costs of ~$9.0 to $12.0M.
      • prior guidance was for 18.5-20.5%
    • Reaffirms effective tax rate is estimated to be in the range of 25.5% to 26.5%, including both federal and state income tax rates as well as international income tax rates, and assumes minimal impact from recently passed tax legislation.
    • Capital expenditures are now estimated to be in the range of $150.0M to $160.0M, which includes ~$75.0M to $80.0M remaining for both the Columbus, Ohio facility expansion and the new Gallatin, Tennessee facility construction.
      • prior guidance was $140.0-160.0M
  • Management Comments:
    • Mike Olosky, President and CEO: "Our pricing actions, particularly in response to tariff pressures and a positive impact from foreign exchange, drove net sales growth of over 6%."
  • Increases share repurchase authorization; authorizes $150.0M for repurchases in 2026:
    • On 23-Oct-25, the company's board increased the 2025 share repurchase authorization by an additional $20.0M, with an aggregate $30.0M now available for repurchases of the company's common stock through 31-Dec-25.
    • On 23-Oct-25, the board authorized the company to repurchase up to $150.0M of the company's common stock, effective 1-Jan-26 through 31-Dec-26.

10/27/2025

Universal Health Services reports Q3 EPS $5.69 ex-items vs FactSet $4.88 [17 est, $4.30-5.98] ($214.03, 0.00)

  • Reports Q3:
    • Included adjusted EPS were the following items which were not included in 2025 operating results forecast as previously disclosed on 28-Jul-25:
      • i) $90M of pre-tax reimbursements (net of related provider taxes), covering the period of 1-Oct-24 through 30-Sep-25, in connection with a recently approved Medicaid state directed payment program in Washington, D.C., and;
      • ii) a $35M pre-tax charge incurred to increase reserves for self-insured professional and general liabilities resulting from unfavorable claims' trends.
    • Revenue $4.50B vs FactSet $4.34B [15 est, $4.27-4.50B]
    • Adjusted EBITDA net of NCI $684.2M vs StreetAccount $603.6M
  • FY Guidance (Dec 2025):
    • EPS $21.50-22.10 per share ex-items vs prior guidance $20.00-21.00 per share and FactSet $20.65 [18 est, $19.20-21.84]
    • Revenue $17.306-17.445B vs prior guidance $17.096-17.312B and FactSet $17.20B [17 est, $17.10-17.37B]
    • Adjusted EBITDA net of NCI $2.569-2.619B vs prior guidance $2.458-2.543B and FactSet $2.53B [19 est, $2.46-2.67B]
  • Increased Repurchase Authorization
    • On 27-Oct-25, the UHS board authorized a $1.5B increase to its stock repurchase program
    • Including today's increased authorization the company currently has a current aggregate available repurchase authorization of $1.759B

10/27/2025

Insider transaction: Pathward Financial President Anthony Sharett discloses sale of 11.5K shares - Form 4 ($70.17, 0.00)

  • Sharett beneficially owns 25.2K shares of common stock following the transaction.

10/27/2025

KB Home board authorizes repurchase of up to $1B of outstanding common stock, replacing prior authorization ($63.11, 0.00)

10/27/2025

ETHZilla Corporation sells ~$40M ETH to facilitate stock repurchases ($20.65, 0.00)

  • ETHZilla Corporation announced that it sold ~$40M of its ETH treasury holdings and plans to use the proceeds for share repurchases.
    • Since executing the sale on 24-Oct-25, the company has repurchased ~600,000 shares of its common stock for ~$12M under its existing board authorized $250M stock repurchase program.
    • ETHZilla plans to use the remaining proceeds of its ETH sale for additional share repurchases and intends to continue to sell ETH to repurchase its shares until the discount to NAV is normalized.
    • ETHZilla continues to hold ~$400M of ETH on its balance sheet to support future strategic initiatives.